| Cancer-Related Anemia (CRA) is a common complication in cancer patients and seriously affects the quality of life and prognosis of patients. Its pathogenesis is complex.Inflammatory factors can activate various signaling pathways and up-regulate hepcidin, thereby affecting iron metabolism (such as hepcidin, BMP6 gene, ferritin, and transferrin) and erythropoiesis through multiple pathways, including regulating iron metabolism, inhibiting the erythropoietin (EPO) signaling pathway, and directly damaging bone marrow hematopoietic function. Genetic mutations (including mutations in genes related to iron metabolism, erythropoiesis, DNA repair and bone marrow suppression, and inflammation), abnormal tumor microenvironment, and abnormal signaling pathways (such as JAK/STAT pathway, NF-κB pathway, and TGF-β/Smad pathway) are all associated with the occurrence of cancer-related anemia (CRA).This paper reviews the latest research progress in the pathogenesis of Cancer-Related Anemia (CRA), aiming to provide a theoretical basis for clinical practice. |
